Download pdf EBMT to track long-term outcome data for Yescarta®, a CAR T therapy for adults living with two types of aggressive non-Hodgkin lymphoma The EBMT announces a new collaboration with Kite, a Gilead Company, to study the long-term outcomes of patients treated with Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor T cell (CAR T) therapy.
Download pdf Press Release 2nd EU Meeting CAR T Cell Meeting Over 1,200 European researchers, clinicians, nurses, patients, regulators, and industry are gathering in Sitges for the 2 nd European CAR T Cell Meeting, organized by the EBMT and EHA.
Download PDF Press Release 2nd EU Meeting CAR T Cell Meeting CAR T Cell Therapy; updates on efficacy and targets in 2nd European Meeting organized by EBMT and EHA in Sitges (Barcelona), Spain, on January 30 - February 1, 2020.